No Cover Image

Journal article 1900 views 217 downloads

Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial

T. Heise, Steve Bain Orcid Logo, Richard Bracken Orcid Logo, E. Zijlstra, L. Nosek, K. Stender‐Petersen, R. Rabøl, E. Rowe, H. L. Haahr

Diabetes, Obesity and Metabolism, Volume: 18, Issue: 2, Pages: 196 - 199

Swansea University Authors: Steve Bain Orcid Logo, Richard Bracken Orcid Logo

  • BrackenSimilarRisk.pdf

    PDF | Version of Record

    This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, providedthe original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

    Download (198.27KB)

Check full text

DOI (Published version): 10.1111/dom.12588

Abstract

We compared changes in blood glucose (BG) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes (T1D) treated with insulin degludec (IDeg) or insulin glargine (IGlar) in a randomized, open-label, two-period, crossover trial. After individual titration and a steady-s...

Full description

Published in: Diabetes, Obesity and Metabolism
ISSN: 1462-8902 1463-1326
Published: Wiley 2016
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa27008
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2016-04-01T01:04:32Z
last_indexed 2023-01-11T13:59:14Z
id cronfa27008
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-12-02T19:09:33.5923654</datestamp><bib-version>v2</bib-version><id>27008</id><entry>2016-03-31</entry><title>Similar risk of exercise&#x2010;related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross&#x2010;over trial</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>f5da81cd18adfdedb2ccb845bddc12f7</sid><ORCID>0000-0002-6986-6449</ORCID><firstname>Richard</firstname><surname>Bracken</surname><name>Richard Bracken</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2016-03-31</date><deptcode>BMS</deptcode><abstract>We compared changes in blood glucose (BG) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes (T1D) treated with insulin degludec (IDeg) or insulin glargine (IGlar) in a randomized, open-label, two-period, crossover trial. After individual titration and a steady-state period, patients performed 30&#x2009;min of moderate-intensity cycle ergometer exercise (65% peak rate of oxygen uptake). BG, counter-regulatory hormones and hypoglycaemic episodes were measured frequently during and for 24&#x2009;h after exercise. BG changes during exercise were similar with IDeg and IGlar [estimated treatment difference (ETD) for maximum BG decrease: 0.14&#x2009;mmol/l; 95% confidence interval (CI) -0.15, 0.42; p&#x2009;=&#x2009;0.34], as was mean BG (ETD -0.16&#x2009;mmol/l; 95% CI -0.36, 0.05; p&#x2009;=&#x2009;0.13). No hypoglycaemic episodes occurred during exercise. Post-exercise mean BG, counter-regulatory hormone response and number of hypoglycaemic episodes in 24&#x2009;h after starting exercise were similar with IDeg (18 events in 13 patients) and IGlar (23 events in 15 patients). This clinical trial showed that, in patients with T1D treated with a basal-bolus regimen, the risk of hypoglycaemia induced by moderate-intensity exercise was low with IDeg and similar to that with IGlar.</abstract><type>Journal Article</type><journal>Diabetes, Obesity and Metabolism</journal><volume>18</volume><journalNumber>2</journalNumber><paginationStart>196</paginationStart><paginationEnd>199</paginationEnd><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1462-8902</issnPrint><issnElectronic>1463-1326</issnElectronic><keywords/><publishedDay>1</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2016</publishedYear><publishedDate>2016-02-01</publishedDate><doi>10.1111/dom.12588</doi><url>http://dx.doi.org/10.1111/dom.12588</url><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2022-12-02T19:09:33.5923654</lastEdited><Created>2016-03-31T20:31:45.7714005</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>T.</firstname><surname>Heise</surname><order>1</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>2</order></author><author><firstname>Richard</firstname><surname>Bracken</surname><orcid>0000-0002-6986-6449</orcid><order>3</order></author><author><firstname>E.</firstname><surname>Zijlstra</surname><order>4</order></author><author><firstname>L.</firstname><surname>Nosek</surname><order>5</order></author><author><firstname>K.</firstname><surname>Stender&#x2010;Petersen</surname><order>6</order></author><author><firstname>R.</firstname><surname>Rab&#xF8;l</surname><order>7</order></author><author><firstname>E.</firstname><surname>Rowe</surname><order>8</order></author><author><firstname>H. L.</firstname><surname>Haahr</surname><order>9</order></author></authors><documents><document><filename>0027008-20072016154459.pdf</filename><originalFilename>BrackenSimilarRisk.pdf</originalFilename><uploaded>2016-07-20T15:44:59.7000000</uploaded><type>Output</type><contentLength>194210</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><embargoDate>2016-07-20T00:00:00.0000000</embargoDate><documentNotes>This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, providedthe original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</documentNotes><copyrightCorrect>true</copyrightCorrect></document></documents><OutputDurs/></rfc1807>
spelling 2022-12-02T19:09:33.5923654 v2 27008 2016-03-31 Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false f5da81cd18adfdedb2ccb845bddc12f7 0000-0002-6986-6449 Richard Bracken Richard Bracken true false 2016-03-31 BMS We compared changes in blood glucose (BG) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes (T1D) treated with insulin degludec (IDeg) or insulin glargine (IGlar) in a randomized, open-label, two-period, crossover trial. After individual titration and a steady-state period, patients performed 30 min of moderate-intensity cycle ergometer exercise (65% peak rate of oxygen uptake). BG, counter-regulatory hormones and hypoglycaemic episodes were measured frequently during and for 24 h after exercise. BG changes during exercise were similar with IDeg and IGlar [estimated treatment difference (ETD) for maximum BG decrease: 0.14 mmol/l; 95% confidence interval (CI) -0.15, 0.42; p = 0.34], as was mean BG (ETD -0.16 mmol/l; 95% CI -0.36, 0.05; p = 0.13). No hypoglycaemic episodes occurred during exercise. Post-exercise mean BG, counter-regulatory hormone response and number of hypoglycaemic episodes in 24 h after starting exercise were similar with IDeg (18 events in 13 patients) and IGlar (23 events in 15 patients). This clinical trial showed that, in patients with T1D treated with a basal-bolus regimen, the risk of hypoglycaemia induced by moderate-intensity exercise was low with IDeg and similar to that with IGlar. Journal Article Diabetes, Obesity and Metabolism 18 2 196 199 Wiley 1462-8902 1463-1326 1 2 2016 2016-02-01 10.1111/dom.12588 http://dx.doi.org/10.1111/dom.12588 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2022-12-02T19:09:33.5923654 2016-03-31T20:31:45.7714005 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine T. Heise 1 Steve Bain 0000-0001-8519-4964 2 Richard Bracken 0000-0002-6986-6449 3 E. Zijlstra 4 L. Nosek 5 K. Stender‐Petersen 6 R. Rabøl 7 E. Rowe 8 H. L. Haahr 9 0027008-20072016154459.pdf BrackenSimilarRisk.pdf 2016-07-20T15:44:59.7000000 Output 194210 application/pdf Version of Record true 2016-07-20T00:00:00.0000000 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, providedthe original work is properly cited, the use is non-commercial and no modifications or adaptations are made. true
title Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial
spellingShingle Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial
Steve Bain
Richard Bracken
title_short Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial
title_full Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial
title_fullStr Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial
title_full_unstemmed Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial
title_sort Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
f5da81cd18adfdedb2ccb845bddc12f7
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
f5da81cd18adfdedb2ccb845bddc12f7_***_Richard Bracken
author Steve Bain
Richard Bracken
author2 T. Heise
Steve Bain
Richard Bracken
E. Zijlstra
L. Nosek
K. Stender‐Petersen
R. Rabøl
E. Rowe
H. L. Haahr
format Journal article
container_title Diabetes, Obesity and Metabolism
container_volume 18
container_issue 2
container_start_page 196
publishDate 2016
institution Swansea University
issn 1462-8902
1463-1326
doi_str_mv 10.1111/dom.12588
publisher Wiley
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
url http://dx.doi.org/10.1111/dom.12588
document_store_str 1
active_str 0
description We compared changes in blood glucose (BG) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes (T1D) treated with insulin degludec (IDeg) or insulin glargine (IGlar) in a randomized, open-label, two-period, crossover trial. After individual titration and a steady-state period, patients performed 30 min of moderate-intensity cycle ergometer exercise (65% peak rate of oxygen uptake). BG, counter-regulatory hormones and hypoglycaemic episodes were measured frequently during and for 24 h after exercise. BG changes during exercise were similar with IDeg and IGlar [estimated treatment difference (ETD) for maximum BG decrease: 0.14 mmol/l; 95% confidence interval (CI) -0.15, 0.42; p = 0.34], as was mean BG (ETD -0.16 mmol/l; 95% CI -0.36, 0.05; p = 0.13). No hypoglycaemic episodes occurred during exercise. Post-exercise mean BG, counter-regulatory hormone response and number of hypoglycaemic episodes in 24 h after starting exercise were similar with IDeg (18 events in 13 patients) and IGlar (23 events in 15 patients). This clinical trial showed that, in patients with T1D treated with a basal-bolus regimen, the risk of hypoglycaemia induced by moderate-intensity exercise was low with IDeg and similar to that with IGlar.
published_date 2016-02-01T03:32:38Z
_version_ 1763751345427316736
score 11.037603

Similar Items